Jabil's 10-K says two things the AI wires missed: half the company is AI capex, and the FDA paused a plant

Jabil▲+2.45% — Jabil, up 2.45 percent today filed its fiscal 2026 annual report↗ on October 23, 2026, and the wire summaries stopped at the headline lines: revenue of $35.95 billion, up 20.6%, and net income of $1.04 billion, up 58.6% ¹. The filing itself carries two more facts those summaries buried, and both move money in opposite directions.

The first fact: half the company is now the AI buildout. The second fact: a regulator has idled one of its plants. Neither is priced in a stock that, as of October 20, 2026, closed at $277.18 and had returned five times a $100 investment since fiscal 2021 against $183 for the S&P 500 ².

Half the company is now the AI story

Jabil's Intelligent Infrastructure segment, the unit building cloud and data center infrastructure, networking gear and capital equipment for AI customers, grew 45% in fiscal 2026 and reached 50% of total revenue, up from 41% in fiscal 2025 and 32% in fiscal 2024 ². In dollars that is $17.87 billion of the $35.95 billion total, against $12.32 billion a year earlier ². The 10-K attributes the rise to AI-related demand across cloud and data center infrastructure, which grew 33% from existing customers, networking and communications at 8%, and capital equipment at 4% ².

That mix shift is what lifted the whole company. Gross margin rose to 9.2% from 8.9%, which the filing ties primarily to product mix in Intelligent Infrastructure ². Core operating income in the segment was $1.07 billion at a 6.0% margin, up from $664 million at 5.4% a year earlier, the fastest growth of the three segments ².

The concentration nobody is pricing

Concentration followed the growth. One unnamed customer, reported primarily through Intelligent Infrastructure, accounted for 20% of fiscal 2026 revenue and 33% of accounts receivable, up from 16% and 24% a year earlier ². The five largest customers together were 37% of revenue ².

Jabil's own risk factors say customers that do not commit to production schedules beyond a quarter, and emerging companies with thinner credit, can hit the company twice: orders cancel and the receivables and inventory already booked do not come back ². The filing also discloses that Jabil sometimes offers such customers extended payment terms, loans and other financial support, which it says has impacted financial results in the past ².

The money at stake is concrete. Management told analysts on September 30 that fiscal 2027 brings $44.5 billion of total revenue, core EPS of $17.55, and $22.1 billion of AI-related revenue, up 54% ³. Earnings that grow 65% a year on a 9% gross margin are earnings that lean hard on a handful of buyers staying solvent and spending ². The 10-K states plainly that a reduction in business from one or more of the largest customers could have a material adverse effect ².

The other half: a regulator shut a line Jabil bought 18 months ago

The overlooked item sits in one paragraph of the filing. On August 27, 2026, Jabil received an FDA warning letter relating to a March 2026 inspection of the Pharmaceutics International Inc. facility in Hunt Valley, Maryland, with findings on manufacturing practices and quality systems ². Management has paused manufacturing at the site, made leadership changes, and launched a comprehensive corrective action plan; full remediation begins once the FDA approves the plan ².

The context makes it more than a footnote. Jabil paid $309 million for Pii in February 2025 to buy aseptic filling, lyophilization and oral solid dose capacity for its Regulated Industries segment, recording $142 million of goodwill on the deal ². The 10-K notes Jabil conducts no aseptic filling at any other location, so the paused line is the aseptic line ². The same filing's risk factors warn that FDA enforcement can escalate from warning letters to fines, recalls or temporarily halting a facility outright ².

How the market read the letter

Scale check, before anyone over-weights it: Regulated Industries revenue grew 7% to $12.69 billion in fiscal 2026, and the warning letter touches one site inside that business ².

Analysts read it the same way. When the letter surfaced, Jabil shares closed at $221.73 on September 2, 2026, down 1.63%, and the average analyst target from nine covering analysts↗ stood at $223.89, with a high of $245 and a low of $205, roughly 0.67% below the then-current price ⁴. The market treated the plant as contained. The filing neither quantifies the revenue at the site nor discloses any remediation cost, so that treatment is an assumption, not a measurement.

What the filing actually says about both halves

The 10-K does not connect the two facts, and the connection runs one way ². The AI segment funds the balance sheet: operating cash flow was $2.0 billion and adjusted free cash flow $1.53 billion in fiscal 2026, with capital expenditures of $628 million against a fiscal 2027 guide of 1.5% to 2.0% of revenue, and $3.4 billion of notes payable against $4.4 billion of unused revolving and receivables capacity ². The plant pause is a working capital and timing problem at worst, absorbed inside a segment growing 7% ².

The question that actually matters

The real question the filing leaves open is not the plant. It is whether the AI concentration earns its risk. A customer at 20% of revenue and 33% of receivables, in a segment whose buyers finance themselves in a credit market that repriced this month, is a larger exposure than the plant pause the wires missed ²⁵.

The corrective-action plan at Hunt Valley has a date to watch, FDA approval of the remediation plan ². The other watch item has no date: what happens to $22.1 billion of guided AI revenue if any hyperscale buyer slows its capex, which the fiscal 2027 quarters will reveal in order flow long before the annual report does ³.

Jabil's own words make the point best: five customers are 37% of revenue, and the company's credit risk language around them has been there all along. The AI half of Jabil compounds earnings; it also concentrates them. The filing says both. Price both.

Deep dive: where to check the numbers

Read the source documents directly. The 10-K is at the SEC's EDGAR system under accession 0001628280-26-067038, filed October 23, 2026, for the fiscal year ended August 31, 2026, signed by CEO Michael Dastoor, CFO Gregory Hebard and Chairman Steven Raymund ².

The segment table in Note 13 gives the Intelligent Infrastructure revenue and margin detail, the concentration table in the same note names the 20% customer by percentage, and the Certain Regulatory Matters section carries the FDA warning letter paragraph ². The earnings call record from September 30, 2026, carries the fiscal 2027 guidance language in management's own words, including CFO Hebard's confirmation of Q4 revenue of approximately $10.6 billion, GAAP EPS of $3.76 and core EPS of $4.40, and CEO Dastoor's $22.1 billion AI-related revenue target ³. For the market side, the ad-hoc-news compilation of September 3, 2026, has the Zacks analyst-target table around the FDA letter ⁴. Each figure in this piece traces to one of those documents; none of it is a restatement of another summary.